P031 Probiotic bacteria enhance antigen sampling and processing by dendritic cells in pediatric IBD

all prescribedmedications. Demographic, dietary and clinical information, PCDAI, Harvey Bradshaw (HB) and Lewis score (LS) were collected at 0, 12 and 52 weeks. CE’s were evaluated by an experienced reader blinded to patient clinical information and timing. Results: Sixteen patients were screened; 10 enrolled; and 9 completed the initial 12 week trial; receiving 85% of estimated caloric needs prior to, and 101%, on the SCD. HB significantly decreased from 3.3 +2.0 to 0.6 +1.3 (p=0.007) as did PCDAI (21.1 +5.9 to 7.8 +7.1; p=0.011). LS declined significantly from 2153+732 to 960+433 (p=0.012). Seven patients continued the SCD to 52weekswith HB (0.1 +0.4) and PCDAI (5.4 +5.5) remaining improved (p=0.016 and 0.027 compared to baseline) withmean LS at 1046 +372 and 2 patients showing sustained mucosal healing. Conclusions: Clinical and mucosal improvements were seen in childrenwith CD using the SCD over 12 and 52weeks. Additionally, CE can monitor mucosal improvement in treatment trials for pediatric CD. Further studies are critically needed to understand the mechanisms underlying SCD’s effectiveness in children with CD.